OncoMatch/Clinical Trials/NCT04389086
Induction Chemotherapy for Locally Recurrent Rectal Cancer
Official title: Multicentre, Open-label, Randomised, Controlled, Parallel Arms Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone as Neoadjuvant Treatment for Locally Recurrent Rectal Cancer - PelvEx II
Is NCT04389086 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies Combination drug for recurrent rectal cancer.
Treatment: Combination drug — This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: DPYD homozygous deficiency
Known homozygous DPD deficiency
Performance status
WHO 0–1
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04389086 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy disqualifies patients from enrollment.
Are patients with DPYD alterations eligible?
No. DPYD homozygous deficiency is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages